← 블로그 목록으로
COLUMN

Why Policy Chaos Is Crushing Your Stock-Picking Edge

Tariffs reversed by courts, blizzards grounding airlines—fundamentals matter less when the game board keeps flipping. Here's what still works.

📅 2026년 2월 23일👁 0 조회

Picture a concert pianist mid-Rachmaninoff as stagehands rearrange the platform beneath him. That's equity markets in February 2025. Eli Lilly just launched a sleeker Zepbound pen—brilliant operational execution—while the Supreme Court struck down Trump tariffs on Friday, only for the White House to signal workarounds by Monday. Meanwhile, a blizzard shutters East Coast airports through Tuesday, erasing leisure travel margins that were never durable to begin with.

The pattern isn't sector rotation. It's a structural break: policy uncertainty now swamps company-specific fundamentals. European trade officials called it "pure tariff chaos," and they're right to panic. When courts override executive orders and Anthropic's CEO rushes to the Pentagon to ensure AI models don't become autonomous kill switches, you're not pricing earnings multiples—you're pricing institutional paralysis.

The bull case says chaos rewards nimble traders. True, if you're running a vol desk. For allocators, it's poison. Lilly's GLP-1 franchise thrives because demand is non-discretionary and tariff-proof; patients don't stop injections when Commerce Department lawyers argue jurisdiction. Contrast that with airlines: no pricing power, weather-exposed, and capital-intensive. Delta can waive change fees all it wants—it can't waive physics or Congress.

The contrarian view holds that quality always wins. But quality without rule-of-law clarity faces valuation compression anyway. You can be right on Lilly's EBITDA and still watch multiples shrink if AI ethics regulations land badly or if reciprocal tariffs boomerang back via emergency orders.

The trade isn't guessing the next decree. It's stress-testing exposure to decree risk itself. Tilt toward companies serving inelastic demand—pharmaceuticals, not discretionary travel. Diversify away from DC-dependent sectors; Europe's exasperation signals fracturing trade architecture. Keep cash for dislocations; they're coming whether earnings beat or not. If you want to catch these subtle shifts in real-time, CREST's analytical tools are worth exploring. Stop forecasting policy. Start positioning for its absence.
#policy uncertainty#volatility#pharma#tariffs#portfolio strategy

📌 참고 자료

https://www.cnbc.com/2026/02/21/blizzard-prompts-airlines-waive-flight-change-fees.htmlhttps://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.htmlhttps://www.cnbc.com/2026/02/23/trump-15percent-global-tariff-europe-eu-uk-reaction.html

🔗 이 글 공유하기

🔔 실시간 매도 신호 받기

무료로 가입하고 보유 종목의 매도 타이밍을 실시간으로 확인하세요.

무료로 시작하기 →